Venule Endothelial Cell Gene Targeting for Local Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory drugs affect both healthy and damaged tissues systemically, leading to adverse side effects such as gastrointestinal and renal issues, and increased susceptibility to infection, with no FDA-approved agents that selectively target the endothelium or tissue-specific vascular beds promoting inflammation.
Innovation Solution
A method of modulating the venuleness of endothelial cells by contacting them with agents that differentially express genes specific to venule or non-venule endothelial cells, altering their phenotype to either venule or non-venule characteristics, thereby interfering with leukocyte interactions and inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current anti-inflammatory drugs are administered systemically, then inflammatory responses are suppressed, but adverse side effects occur in healthy tissues including gastrointestinal and renal issues and increased susceptibility to infection
Solution Approach 1:
The patent applies local quality by developing agents that specifically target venular endothelium in inflamed tissues rather than acting systemically. The compounds selectively bind to VCAM-1 and VEGFR-2 expressed on venular endothelial cells at inflammation sites, producing anti-inflammatory effects locally without affecting healthy tissues systemically, thereby resolving the contradiction between suppressing inflammation and avoiding adverse side effects
Solution Approach 2:
The patent uses venular endothelium as an intermediary target. The anti-inflammatory agents do not directly act on inflamed tissues or leukocytes but instead modulate the venular endothelium's expression of adhesion molecules and cytokines, which then mediate the anti-inflammatory effect by regulating leukocyte recruitment and vascular permeability at the inflammation site
2Manufacturing precision
If anti-inflammatory agents are designed to target endothelium selectively, then specificity is improved, but device complexity and development difficulty increase
Solution Approach 1:
The patent achieves selective targeting by exploiting parameter differences in gene expression between venular and other endothelial cells. The agents target specific parameters (VCAM-1, VEGFR-2 expression levels) that are uniquely elevated on venular endothelium during inflammation, allowing high specificity without requiring complex delivery systems or multiple components
Data Source
AI summary
Disclosed herein are genes which are differentially expressed in venule endothelial cells (V-ECs) compared to non-venule endothelial cells (NV-ECs) and methods and compositions relating to those genes. Also disclosed herein are methods of modulating the venuleness of an endothelial cell or microvessel, methods of modulating leukocyte trafficking, methods of modulating inflammation, methods of targeting agents to tissues based on their ability to bind to surface markers expressed in a microvessel (e.g., venules and non-venules), methods of identifying the venuleness of endothelial cells or microvessels, methods of identifying agents that modulate the venuleness of endothelial cells or microvessels, methods of identifying agents that target microvessels, methods for treating diseases associated with leukocyte trafficking, methods for treating inflammatory diseases, and compositions and kits for use in the methods.